RocketTickers

NGM Bio’s NGM621 Receives Fast Track Designation from the FDA fo

Long
NASDAQ:NGM   NGM Biopharmaceuticals, Inc
NGM: NGM Biopharmaceuticals, Inc.
2022-02-07 08:00:00
NGM Bio’s NGM621 Receives Fast Track Designation from the FDA for the Treatment of Patients with Geographic Atrophy Secondary to Age-Related Macular Degeneration
Disclaimer

The information and publications are not meant to be, and do not constitute, financial, investment, trading, or other types of advice or recommendations supplied or endorsed by TradingView. Read more in the Terms of Use.